Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the 5-year overall survival (OS) results of CPX-351 (Vyxeos) versus 7+3 (cytarabine and anthracycline) in patients with newly diagnosed high-risk or secondary acute myeloid leukemia (AML).
Eighteen percent of patients who received CPX-351 were alive at 5 years compared with 8% who received 7+3. Cortes says there was clearly still a benefit long term and although the investigators would like to see higher OS rates, the doubling of survival in the CPX-351 arm was important.
The subgroup analyses showed that the benefits of CPX-351 were maintained across age groups on this phase 3 trial. The 3-year survival in the patients 60 to 69 years old, was 23% versus 14% for CPX-351 and 7+3, respectively. For patients 70 to 75 years old, there was an 18% 3-year OS rate for CPX-351 compared with 0% with 7+3. At 5 years, the OS was 20% in the younger population receiving CPX-351 and 12% for those receiving 7+3. For the older population, the survival rate at 5 years was 16% versus 0%, respectively. The benefit with CPX-351 was applicable to both age groups, according to Cortes.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More